GenapSys, a Redwood City, CA-based company developing a scalable electronic sequencing platform, raised $70m in Series D equity financing.
Backers included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors. In conjunction with the funding, Bob Zollars and a representative of Farallon Capital have been appointed to GenapSys’ Board of Directors.
The company intends to use the funds to continue advancing its semiconductor based next-generation sequencing (NGS) platform.
Led by Jason Myers, Ph.D., Chief Executive Officer, and Founder and Chairman Dr. Hesaam Esfandyarpour, GenapSys is a company focused on the advancement of universal access to genomic information by delivering a genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. GenapSys products are provided for Research Use Only. Not for use in diagnostic procedures.